A Fourteen-day Experience with Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS) : An Iranian Treatment Protocol
COVID-19 is currently causing concern in the medical community as the virus is spreading around the world. It has a heavy global burden, particularly in low-income countries. The clinical spectrum of COVID-19 pneumonia ranges from mild to critically ill cases and Acute Respiratory Distress Syndrome. An expert panel was held and an internal protocol was developed to manage the COVID-19 induced ARDS according to WHO recommendations and NIH guidelines. Different therapeutic regimens were employed on this protocol based on the ARDS severity and the patients' special characteristics. The mortality rate, the rate of survivors, and non-survivors were reported. Of the 231 suspected cases of COVID-19 admitted to the hospital during two weeks, 72 patients were admitted to ICU with diagnosis confirmed by RT-PCR. In total, mortality in the ICU was 25% (n = 18) among ARDS patients over two weeks. COVID-19 induced ARDS is a major concern. The rapid progression of ARDS needs specific protocol based on patients' characteristics and rapid action.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Iranian journal of pharmaceutical research : IJPR - 19(2020), 1 vom: 15., Seite 31-36 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jamaati, Hamidreza [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute respiratory distress syndrome |
|---|
| Anmerkungen: |
Date Revised 28.09.2020 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.22037/ijpr.2020.113337.14239 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314945423 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314945423 | ||
| 003 | DE-627 | ||
| 005 | 20231225153835.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.22037/ijpr.2020.113337.14239 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1049.xml |
| 035 | |a (DE-627)NLM314945423 | ||
| 035 | |a (NLM)32922466 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jamaati, Hamidreza |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Fourteen-day Experience with Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS) |b An Iranian Treatment Protocol |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.09.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a COVID-19 is currently causing concern in the medical community as the virus is spreading around the world. It has a heavy global burden, particularly in low-income countries. The clinical spectrum of COVID-19 pneumonia ranges from mild to critically ill cases and Acute Respiratory Distress Syndrome. An expert panel was held and an internal protocol was developed to manage the COVID-19 induced ARDS according to WHO recommendations and NIH guidelines. Different therapeutic regimens were employed on this protocol based on the ARDS severity and the patients' special characteristics. The mortality rate, the rate of survivors, and non-survivors were reported. Of the 231 suspected cases of COVID-19 admitted to the hospital during two weeks, 72 patients were admitted to ICU with diagnosis confirmed by RT-PCR. In total, mortality in the ICU was 25% (n = 18) among ARDS patients over two weeks. COVID-19 induced ARDS is a major concern. The rapid progression of ARDS needs specific protocol based on patients' characteristics and rapid action | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Acute respiratory distress syndrome | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Coronavirus | |
| 650 | 4 | |a Treatment | |
| 700 | 1 | |a Dastan, Farzaneh |e verfasserin |4 aut | |
| 700 | 1 | |a Tabarsi, Payam |e verfasserin |4 aut | |
| 700 | 1 | |a Marjani, Majid |e verfasserin |4 aut | |
| 700 | 1 | |a Saffaei, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Hashemian, Seyed MohammadReza |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Iranian journal of pharmaceutical research : IJPR |d 2010 |g 19(2020), 1 vom: 15., Seite 31-36 |w (DE-627)NLM232822573 |x 1726-6890 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2020 |g number:1 |g day:15 |g pages:31-36 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.22037/ijpr.2020.113337.14239 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2020 |e 1 |b 15 |h 31-36 | ||